aap: Q1 Sales up 35% close to Break-even Result after first-time
Consolidation of Fame
aap Implantate AG, a medical technology company listed in the Prime
Standard Segment on the Frankfurt Stock Exchange and specialized in
biomaterials and implants for trauma and joint reconstruction,
achieved, consolidated with the first-time incorporated Dutch Fame
Medical Group, 35% sales growth the first three months of financial
year 2007 to EUR 5.9 million (previous year: EUR 4.4 million) and a
slightly negative operating result of EUR 0.1 million (previous year:
EUR 0.7 million). As already announced, this trend was due to a sales
decline at the "old" aap companies after sales of low-margin
merchandise were discontinued and to reduced shipments to a large
customer.
+------------------------------------------------------------------+
| In EUR million | Q1/2007 | Q1/2006 | Change on Year |
| | (incl. Fame) | | |
|---------------------+--------------+------------+----------------|
| Sales | 5.9 | 4.4 | +35% |
|---------------------+--------------+------------+----------------|
| EBITDA | 0.4 | 1.1 | -64% |
|---------------------+--------------+------------+----------------|
| EBIT | -0.1 | 0.7 | -116% |
|---------------------+--------------+------------+----------------|
| EBT | -0.2 | 0.7 | -129% |
|---------------------+--------------+------------+----------------|
| Net Period Result | -0.1 | 0.4 | -130% |
|---------------------+--------------+------------+----------------|
| Equity (Ratio) | 21.5 (37%) | 21.6 (77%) | 0% |
|---------------------+--------------+------------+----------------|
| Balance Sheet Total | 59.0 | 28.0 | +111% |
|---------------------+--------------+------------+----------------|
| Employees | 263 | 161 | +63% |
+------------------------------------------------------------------+
In the first quarter of 2007 the aap Group earned an EBITDA of EUR
0.4 million (previous year: EUR 1.1 million). Group EBIT was EUR
minus 0.1 million (previous year: EUR 0.7 million), EBT EUR minus 0.2
million (previous year: EUR 0.7 million). With a EUR 59.0 million
(previous year: EUR 28.0 million) balance sheet total the equity
ratio is currently 37% because the capital increase has not yet been
completed. After the capital increase it would be 72%.
In the first months of financial year 2007 aap entered into
distribution cooperations on biomaterial products with Zimmer and
Medtronic, global market leaders in the orthopedic and spinal field.
These contracts confirming aap's successful product strategy and good
technological position and will lead to higher sales from the second
half of 2007. For the full year 2007 aap anticipates sales growth,
including Fame, of more than 60% to around EUR 30 million from EUR
18.6 million in 2006.
The full report on aap Implantate AG's first quarter of 2007 is
available to download at www.aap.de.
aap is a medical technology company active in developing,
manufacturing and marketing implants and biomaterials for trauma and
joint reconstruction. Its product portfolio includes implants for
fracture healing and joint replacement, bone cements, bone graft
substitutes and antibiotical carriers. In addition to its Berlin
headquarters the company has locations in Dieburg and Obernburg near
Frankfurt am Main as well as Nijmegen in The Netherlands. Since May
16, 2003 aap Implantate AG has been listed in the Prime Standard
segment on the Frankfurt Stock Exchange.
Please address any queries to:
aap Implantate AG, Nanette Hüdepohl, Investor & Public Relations,
Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9133, fax: +49 30 7501 9290, n.huedepohl@aap.de
--- End of Message ---
aap Implantate AG
Lorenzweg 5 Berlin Germany
WKN: 506660; ISIN:
DE0005066609; Index: CDAX, Prime All Share, TECH All Share;
Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Prime
Standard in Frankfurter Wertpapierbörse,
Freiverkehr in Börse Berlin Bremen, Freiverkehr in Börse Düsseldorf,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Niedersächsische Börse zu Hannover,
Freiverkehr in Bayerische Börse München, Freiverkehr in Börse
Stuttgart;
